Merck & Co., Inc.
MRKNYSE
$144.62
Last price · USD
- Market cap
- $362.6B
- P/E
- 19.9x
- EV / EBITDA
- 14.1x
- P/S
- 5.6x
- FCF yield
- 3.4%
- Div. yield
- 2.26%
Multiples use last price and FY2025 annual figures. Market cap estimated from diluted shares.
Revenue
$64.93B
+1.2%
4Y CAGR +7.5%
Gross profit
$46.73B
-4.6%
4Y CAGR +7.4%
Operating income
$23.49B
+16.1%
4Y CAGR +15.5%
Net income
$18.25B
+6.6%
4Y CAGR +8.8%
EPS (diluted)
$7.28
+8.0%
4Y CAGR +9.1%
Free cash flow
$12.36B
-31.7%
4Y CAGR +6.4%
Revenue & net income
Fiscal 2021–2025 · USD
RevenueNet income
Valuation
At $144.62 · FY2025 fundamentals
- Market cap
- $362.6B
- Enterprise value
- $398.5B
- P/E
- 19.9x
- P/S
- 5.6x
- P/B
- 6.9x
- EV / EBITDA
- 14.1x
- EV / Sales
- 6.1x
- Earnings yield
- 5.0%
- FCF yield
- 3.4%
- Shareholder yield
- 3.7%
Profitability
Margins as a share of revenue
| Metric | Latest | 4Y ago | Trend |
|---|---|---|---|
| Gross margin | 72.0%-0.0pp | 72.0% | |
| Operating margin | 36.2%+9.1pp | 27.1% | |
| EBITDA margin | 43.5%+6.8pp | 36.8% | |
| Net margin | 28.1%+1.3pp | 26.8% | |
| FCF margin | 19.0%-0.8pp | 19.8% |
Returns & financial health
FY2025 with 4-year trend
| Metric | Latest | 4Y ago | Trend |
|---|---|---|---|
| Return on equity | 34.7% | 34.2% | |
| Return on invested capital | 23.0% | 18.2% | |
| Return on assets | 13.3% | 12.3% | |
| Debt / equity | 0.96x | 0.91x | |
| Net debt / EBITDA | 1.27x | 1.48x | |
| Current ratio | 1.54x | 1.27x |
Cash & equivalents
$14.56B
Total debt
$50.53B
Capital allocation
How MRK used its cash in FY2025
- Operating cash flow
- $16.47B
- Capital expenditure
- $4.11B
- Dividends paid
- $8.18B
- Share repurchases
- $5.08B
- Stock-based compensation
- $0.00
- Diluted shares
- 2.51B
- Share count change (4Y)
- -1.2%
Analyst estimates
Consensus for upcoming fiscal years
| Fiscal year | Revenue | Growth | EPS | Growth |
|---|---|---|---|---|
| FY2025 actual | $64.93B | $7.28 | ||
| FY2026E13 analysts | $67.04B | +3.2% | $2.65 | -63.6% |
| FY2027E12 analysts | $69.77B | +4.1% | $9.23 | +248.5% |
| FY2028E7 analysts | $73.88B | +5.9% | $10.17 | +10.3% |
About Merck & Co., Inc.
Healthcare · Drug Manufacturers - General
Merck & Co. , Inc. is a global healthcare leader with operations spanning two core divisions: Pharmaceuticals and Animal Health.
merck.com- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Robert Davis
- Employees
- 74,000
- Headquarters
- Rahway, NJ, US
- IPO date
- 1978-01-13
Merck & Co., Inc. (MRK) — frequently asked questions
Answered from the company's SEC filings
Merck & Co. , Inc.
Explore the full income statement, balance sheet and cash flow statement. Not investment advice.